Abstract
Idrapril, the prototype of a new clinical class of ACE inhibitors, has a pharmacological profile similar to captopril in animals. Preliminary experimental data suggest a lower potential for inducing cough compared to captopril. In humans, it has a short elimination half-life of about 2 h, but a much longer effect on RAS and blood pressure (12 to 24 h), without affecting heart rate.
| Original language | English |
|---|---|
| Pages (from-to) | 351-363 |
| Number of pages | 13 |
| Journal | Cardiovascular Drug Reviews |
| Volume | 14 |
| Issue number | 4 |
| Publication status | Published - 1996 |
Keywords
- Angiotensin-converting enzyme inhibitor
- Antihypertensives
- Heart
- Idrapril
ASJC Scopus subject areas
- Pharmacology
- Cardiology and Cardiovascular Medicine